Literature DB >> 33847907

Reversing Accumulation of Polyglucosan Bodies by Virally Delivered CRISPR/Cas9 Genome Editing.

Antonella Riva1,2, Pasquale Striano3,4.   

Abstract

Entities:  

Keywords:  Genome editing; Lafora disease; Polyglucosan bodies; Precision medicine; Treatment

Mesh：

Substances：

Year:  2021        PMID： 33847907      PMCID： PMC8423881          DOI： 10.1007/s13311-021-01054-1

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN： 1878-7479            Impact factor:   7.620


× No keyword cloud information.
  8 in total

Review 1.  MicroRNAs and pharmacogenomics.

Authors:  Noam Shomron
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

2.  Epilepsy treatment: precision medicine at a crossroads.

Authors:  Dick Lindhout
Journal:  Lancet Neurol       Date:  2015-12       Impact factor: 44.182

Review 3.  From Genetic Testing to Precision Medicine in Epilepsy.

Authors:  Pasquale Striano; Berge A Minassian
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

4.  Reactive Glia-Derived Neuroinflammation: a Novel Hallmark in Lafora Progressive Myoclonus Epilepsy That Progresses with Age.

Authors:  Marcos Lahuerta; Daymé Gonzalez; Carmen Aguado; Alihamze Fathinajafabadi; José Luis García-Giménez; Mireia Moreno-Estellés; Carlos Romá-Mateo; Erwin Knecht; Federico V Pallardó; Pascual Sanz
Journal:  Mol Neurobiol       Date:  2019-12-05       Impact factor: 5.590

Review 5.  Epilepsy in adults.

Authors:  Roland D Thijs; Rainer Surges; Terence J O'Brien; Josemir W Sander
Journal:  Lancet       Date:  2019-01-24       Impact factor: 79.321

Review 6.  The genetic landscape of the epileptic encephalopathies of infancy and childhood.

Authors:  Amy McTague; Katherine B Howell; J Helen Cross; Manju A Kurian; Ingrid E Scheffer
Journal:  Lancet Neurol       Date:  2015-11-17       Impact factor: 44.182

Review 7.  The CRISPR tool kit for genome editing and beyond.

Authors:  Mazhar Adli
Journal:  Nat Commun       Date:  2018-05-15       Impact factor: 14.919

Review 8.  Neuroinflammation and progressive myoclonus epilepsies: from basic science to therapeutic opportunities.

Authors:  Pascual Sanz; José M Serratosa
Journal:  Expert Rev Mol Med       Date:  2020-09-17       Impact factor: 5.600
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.